Eli Lilly partners with ABL Biotech on bispecific antibodies via the Grabody platform in a deal worth up to $2.6B. Read more ...

Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...

The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Historical trends show that even leading firms can experience abrupt market fluctuations, where stocks can plummet ...

We recently published 11 Stocks Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer ...

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? Investors will be watching what Trump makes happen.

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to ...